Drug Approval | December 20, 2025
Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
This marks the first partnership between Pfizer and Cipla in India
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
